Skip to content

The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province

The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03333967
Enrollment
1000
Registered
2017-11-07
Start date
2017-09-01
Completion date
2020-09-01
Last updated
2017-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

apatinib

Brief summary

The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .

Interventions

None listed

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female patients . 2. Confirmed by Pathology or histology of Gastric cancer 3. Patients should be voluntary to the trial and provide with signed informed consent 4. The researchers believe patients can benefit from the study.

Exclusion criteria

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories 2. Pregnant or lactating women 3. Patients with Apatinib contraindications 4. Patients of doctors considered unsuitable for the trial

Design outcomes

Primary

MeasureTime frameDescription
Progress free survival1 yearProgress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.

Secondary

MeasureTime frameDescription
disease control rate1yearInvestigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1
Objective tumor response rate1yearObjective tumor response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments
overall survival3yearoverall survival is defined as the length of time from random assignment to death or to last contact.
Disease-free survival1 yearDisease-free survival is defined as the length of time from the date of randomization to the date of first documentation of relapse of gastric cancer or any other type of cancer or death.

Other

MeasureTime frameDescription
Quality of life score1yearQuality of life score is a questionnaire developed to assess the quality of life of cancer patients.
adverse events1yearadverse events are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.

Countries

China

Contacts

Primary Contactguoping sun, doctor
gpsun_ahmu@126.com0551-62922249

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026